Ada Health and Santéclair Extend Partnership for Three More Years
Ada Health, a leading AI health assessment platform, has announced a three-year extension to its partnership with Santéclair, a French health services management company. This partnership allows Santéclair’s 10 million members to continue utilizing Ada’s automated care navigation technology through MySantéclair, the digital health platform of the French company.
Christian Acknin, director-general of Santéclair, expressed his enthusiasm about the extended partnership, stating that their goal has always been to provide access to quality care for all. By expanding the services directed by Ada’s AI, Santéclair aims to further support its insurance partners’ members throughout their healthcare journey.
Santéclair connects members to over 150,000 healthcare providers in France, covering a wide range of specialties. Ada’s AI technology takes into account members’ insurance coverage to guide them to the most suitable care within this extensive network.
The initial partnership, established in 2021, covers around 60 insurance plans and focuses on empowering members to make informed decisions about their care, directing them to cost-effective services, whether virtual or in-person.
Nicholas Altebrando, chief product officer at Ada Health, highlighted the increasing demand for digital tools that align with individuals’ insurance plans and empower them to manage their own care journey. The partnership with Santéclair delivers precisely that, connecting thousands of individuals to cost-effective services based on their plans and care needs.
The range of services covered by the partnership includes specialists in various fields, condition-specific treatments, preventative services, and patient education for self-management. Ada Health, founded in 2011 and based in Berlin, has become a significant player in the European health AI industry.
In February 2022, Ada Health secured substantial funding for rapid growth, particularly in the US market. Additionally, the company’s solution was certified as a Class IIa medical device under the EU Medical Device Regulation, solidifying its safety and performance standards for the diagnosis and management of health conditions.
